Rehabilitation Treatment in Patients with Ankylosing Spondylitis Stabilized with Tumor Necrosis Factor Inhibitor Therapy. A Randomized Controlled Trial

REFERENCES

1. 1.↵
   1. Sieper J,
   2. Braun J,
   3. Rudwaleit M,
   4. Boonen A,
   5. Zink A

   . Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61 Suppl III:8–18.

   OpenUrl
2. 2.↵
   1. Zochling J,
   2. van der Heijde D,
   3. Burgos-Vargas R,
   4. Collantes E,
   5. Davis JC Jr.,
   6. Dijkmans B,
   7. et al.

   ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442–52.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Barkham N,
   2. Kong KO,
   3. Tennant A,
   4. Fraser A,
   5. Hensor E,
   6. Keenan AM,
   7. et al.

   The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology 2005;44:1277–81.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Vander Cruyssen B,
   2. Ribbens C,
   3. Boonen A

   . The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072–7.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Braun J,
   2. Brandt J,
   3. Listing J,
   4. Zink A,
   5. Alten R,
   6. Golder W,
   7. et al.

   Treatment of active ankylosing spondylitis with infliximab — a double-blind placebo controlled multicenter trial. Lancet 2002;359:1187–93.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Brandt J,
   2. Khariouzov A,
   3. Listing J,
   4. Haibel H,
   5. Sörensen H,
   6. Grassnickel L,
   7. et al.

   Six months results of a German double-blind placebo controlled clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2003;48:1667–75.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. van der Heijde D,
   2. Kivitz A,
   3. Schiff MH,
   4. Sieper J,
   5. Dijkmans BA,
   6. Braun J,
   7. et al.

   Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136–46.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Haibel H,
   2. Rudwaleit M,
   3. Brandt HC,
   4. Grozdanovic Z,
   5. Listing J,
   6. Kupper H,
   7. et al.

   Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678–81.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Davis JC Jr.,
   2. van der Heijde DM,
   3. Braun J,
   4. Dougados M,
   5. Clegg DO,
   6. Kivitz AJ,
   7. et al.

   Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346–52.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Braun J,
    2. Baraliakos X,
    3. Listing J,
    4. Fritz C,
    5. Alten R,
    6. Burmester G,
    7. et al.

    Persistent clinical efficacy and safety of antitumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340–5.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Dagfinrud H,
    2. Kvien TK,
    3. Hagen KB

    . Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008;1:CD002822.

    OpenUrlPubMed
12. 12.↵
    1. Fernandes de las Penas C,
    2. Alonso-Blanco C,
    3. Morales-Cabezas M,
    4. Miangolarra-Page JC

    . Two exercise interventions for the management of patients with ankylosing spondylitis. A randomised controlled trial. Am J Phys Med Rehabil 2005;84:407–19.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Fernandes de las Penas C,
    2. Alonso-Blanco C,
    3. Alguacil-Diego IM,
    4. Miangolarra-Page JC

    . One-year follow-up of two exercise interventions for the management of patients with ankylosing spondylitis: a randomised controlled trial. Am J Phys Med Rehabil 2006;85:559–67.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Lubrano E,
    2. D’Angelo S,
    3. Parsons WJ,
    4. Serino F,
    5. Tanzillo AT,
    6. Olivieri I,
    7. et al.

    Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study. J Rheumatol 2006;33:2029–34.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Spadaro A,
    2. De Luca T,
    3. Massimiani MP,
    4. Ceccarelli F,
    5. Riccieri,
    6. Valesini G

    . Occupational therapy in ankylosing spondylitis: short term prospective study in patients treated with anti TNF alpha drugs. Joint Bone Spine 2008;75:29–33.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Dubey SG,
    2. Leeder J,
    3. Gaffney K

    . Physical therapy in anti TNF treated patients with ankylosing spondylitis. Rheumatology 2008;47:1100–1.

    OpenUrlFREE Full Text
17. 17.↵
    1. Van der Linden S,
    2. Valkenburg HA,
    3. Cats A

    . Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.

    OpenUrlPubMed
18. 18.↵
    1. Jenkinson TR,
    2. Mallorie PA,
    3. Whitelock HC,
    4. Kennedy L,
    5. Garrett SL,
    6. Calin A

    . Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.

    OpenUrlPubMed
19. 19.↵
    1. Garrett S,
    2. Jenkinson T,
    3. Kennedy LG,
    4. Whitelock H,
    5. Gaisford P,
    6. Calin A,
    7. et al.

    A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.

    OpenUrlPubMed
20. 20.↵
    1. Calin A,
    2. Garrett S,
    3. Whitelock H,
    4. Kennedy LG,
    5. O’Hea J,
    6. Mallorie P,
    7. et al.

    T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.

    OpenUrlPubMed
21. 21.↵
    1. Bonaldo L,
    2. Ferraro C,
    3. Miolo M,
    4. Masiero S

    . Valutazione dell’articolarità del rachide in pazienti affetti da Spondilite Anchilosante mediante goniometro ad indice pesante ed ago bussola. Europa Medicophysica 2006;42 Suppl 1:347–50.

    OpenUrl
22. 22.↵
    1. Pesarin F,
    2. Salmaso L

    . Permutation tests for complex data: theory, applications and software. Chichester: Wiley; 2010.
23. 23.↵
    1. Gorman JD,
    2. Sack KE,
    3. Davis JC Jr.

    . Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349–56.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. van der Heijde D,
    2. Dijkmans B,
    3. Geusens P,
    4. et al.

    Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582–91.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Elyan M,
    2. Khan MA

    . Does physical therapy still have a place in the treatment of ankylosing spondylitis? Curr Opin Rheumatol 2008;20:282–6.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Heikkila J,
    2. Viitanen JV,
    3. Kautiainen H,
    4. Kauppi M

    . Sensitivity to change of mobility tests: Effect of short term intensive physiotherapy and exercise on spinal, hip and shoulder measurements in spondyloarthropathy. J Rheumatol 2000;27:1251–6.

    OpenUrlPubMed
27. 27.↵
    1. Widberg K,
    2. Karimi H,
    3. Hafström I

    . Self- and manual mobilization improves spine mobility in men with ankylosing spondylitis: a randomized study. Clin Rehabil 2009;23:599–608.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Turan Y,
    2. Duruöz MT,
    3. Bal S,
    4. Guvenc A,
    5. Cerrahoglu L,
    6. Gurgan A

    . Assessment of fatigue in patients with ankylosing spondylitis. Rheumatol Int 2007;27:847–52.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Roussou E,
    2. Sultana S

    . The Bath Ankylosing Spondylitis Activity and Function Indices (BASDAI and BASFI) and their correlation with main symptoms experienced by patients with spondyloarthritis. Clin Rheumatol 2010;29:869–74.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. van der Heijde D,
    2. van der Linden S,
    3. Bellamy N,
    4. Calin A,
    5. Dougados M,
    6. Khan MA

    . Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 1999;26:945–7.

    OpenUrlPubMed
31. 31.↵
    1. Ton Nghiem FT,
    2. Donohue JP

    . Rehabilitation in ankylosing spondylitis. Curr Opin Rheumatol 2008;20:203–7.

    OpenUrlCrossRefPubMed